STX-1150
/ Scribe Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 08, 2026
STX-1150 Provides Persistent LDL-C Control for at Least Two Years After a Single Dose, a Novel Epigenetic Silencing Approach
(AHA 2026)
- No abstract available
Late-breaking abstract • Atherosclerosis • Cardiovascular • Hematological Disorders • Thrombosis
1 to 1
Of
1
Go to page
1